Research Paper Volume 13, Issue 1 pp 351—363

ADRB1 was identified as a potential biomarker for breast cancer by the co-analysis of tumor mutational burden and immune infiltration

Performance evaluation of TMB and DEGs in the high and low TMB groups. (A) Prognosis of TMB. The survival curves of the high and low TMB groups intersect (P=0.022); (B) The associations of the clinical characteristics with TMB. Higher TMB levels were associated with over 65 years old and the N0 stage (PC) The top 40 DEGs are shown in the heatmap plot. TMB, tumor mutation burden; DEGs, differentially expressed genes; N0, no lymph nodes are involved.

Figure 2. Performance evaluation of TMB and DEGs in the high and low TMB groups. (A) Prognosis of TMB. The survival curves of the high and low TMB groups intersect (P=0.022); (B) The associations of the clinical characteristics with TMB. Higher TMB levels were associated with over 65 years old and the N0 stage (P<0.001); (C) The top 40 DEGs are shown in the heatmap plot. TMB, tumor mutation burden; DEGs, differentially expressed genes; N0, no lymph nodes are involved.